Cautious Approach Needed to HTPs' Harm Reduction Claims: Study

Nov.11.2022
Cautious Approach Needed to HTPs' Harm Reduction Claims: Study
A new study warns that current evidence on heated tobacco products (HTPs) doesn't meet standards, and claims of harm reduction should be taken with caution.

The author of a new study published in "Tobacco Control" has stated that the quality of existing evidence regarding heated tobacco products (HTPs) is insufficient and policymakers should be cautious about claims of harm reduction.


In recent years, HTPs have become popular and supporters insist that they pose less harm to health than traditional cigarettes. However, researchers from the University of Bath argue that the evidence supporting these claims largely fails to account for real-world usage and is subject to a high risk of bias.


In their analysis of 40 publicly disclosed HTP clinical trials, 29 of which were affiliated with or sponsored by the tobacco industry, researchers determined that the majority of existing clinical trials have a "high risk of bias" based on their methods and study design.


The most common reason for research to be at high risk of bias is performance bias, which occurs when participants and those conducting the test are aware of the intervention measures being assigned. Additionally, failure to report all result data from the trial measurements is a flaw known as selective reporting bias.


The author believes that the existence of biases has damaged the validity of the experiment, which may lead to an overestimation of the effectiveness of HTP. They also found further limitations in the experiment, including a short duration, restrictive conditions that do not reflect real-world situations, and a lack of relevant comparators, such as e-cigarettes.


The tobacco control research group in Bath says that more detailed independent studies are necessary to evaluate the short and long-term health effects of HTPs.


At the same time, they believe that consumers should be wary of claims of harm reduction, and policymakers and regulators should carefully consider the role of these trials when making decisions surrounding HTPs.


In recent years, there has been significant development in the heated tobacco market in the UK and around the world. According to Sophie Braznell, Chief Researcher at Bath Health Authority, this growth is premised on the notion that these products are healthier than traditional cigarettes.


Our analysis indicates that the situation is far from clear. Clinical trials used by the tobacco industry to support these claims are often inadequate in terms of research methods and reporting, and most are somehow linked to the tobacco industry.


As more and more consumers are turning away from cigarettes and towards these new generation products, there is a need for better evidence to evaluate their current and future health impact. At the same time, the jury is still out on their potential benefits.


The findings related to clinical trials on heated tobacco products are very important, and we need to remain vigilant about the health claims made," added Gemma Taylor, a co-author of the research report from the Addiction and Mental Health Group and Department of Psychology at the University of Bath.


However, at the same time, it is important to note the clear distinction between "heated tobacco products" and "electronic cigarettes". Consumers and health policy makers must not equate the potential benefits of electronic cigarettes in helping people quit smoking with heated tobacco products.


Statement:


This article is compiled from third-party information and is only intended for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The translation of this article is solely for the purpose of industry exchange and research.


Due to limitations in the translation skills, the translated article may differ from the original text. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on all statements and positions related to domestic issues, as well as those involving Hong Kong, Macau, Taiwan, and foreign affairs.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

UK Directors Banned After 352,688 Vapes Imported From China Were Misdeclared as Medical Nebulizers in £15 Million Tax Case
UK Directors Banned After 352,688 Vapes Imported From China Were Misdeclared as Medical Nebulizers in £15 Million Tax Case
The UK Insolvency Service said YSK Enterprises imported large quantities of vapes from China in 2023, with a shipment addressed to the company declared as medical nebulizers before Border Force found 352,688 vaping products. HMRC calculated nearly £15 million ($20.3 million) in unpaid VAT and customs duty, alongside about £437,000 in corporation tax. Two directors were disqualified for nine years. The case predates the UK's Vaping Products Duty, which will introduce vape-specific excise and duty-stamp requirements from October 2026.
Regulations
Sep.11
Product | BAT Expands VELO Travellers’ Collection With Mexico, Spain and Sweden Summer Edition Nicotine Pouches
Product | BAT Expands VELO Travellers’ Collection With Mexico, Spain and Sweden Summer Edition Nicotine Pouches
British American Tobacco (BAT) Global Travel Retail has expanded the VELO Travellers’ Collection with three new Summer Editions: Mexico, Spain and Sweden. Inspired by destination themes, the new nicotine pouch variants are designed for global travel-retail channels. The launch further strengthens VELO’s positioning as a travel-retail exclusive product collection.
Aug.27
Ohio Supreme Court Weighs Whether State Consumer Law Can Restrict Flavored Vape Sales
Ohio Supreme Court Weighs Whether State Consumer Law Can Restrict Flavored Vape Sales
The Ohio Supreme Court is hearing a case involving flavored vape sales and whether state authorities can use consumer protection laws to take action against retailers selling unauthorized vape products. Ohio officials argue that selling unauthorized flavored vapes may constitute consumer deception, while retailers argue that tobacco product regulation falls under federal Food and Drug Administration (FDA) authority and that states cannot impose additional restrictions through consumer laws. The case could affect the scope of state-level vape regulation across the United States.
Aug.06
BAT Calls for Retailer Input in Future Nicotine Regulations
BAT Calls for Retailer Input in Future Nicotine Regulations
British American Tobacco (BAT) has called for stronger retailer involvement in shaping future nicotine product regulations in the UK, arguing that frontline market feedback should be considered during policy development. BAT said retailers provide direct insight into consumer behavior, market changes and regulatory implementation challenges. The comments come as the UK nicotine market undergoes regulatory changes, including the disposable vape ban, Vaping Products Duty and efforts to address illicit vape sales.
Jul.29
China’s Jiangsu Tobacco Monopoly Bureau and Drug Regulator Target Illegal Vape Sales Disguised as Medical Devices, Define Six Violations
China’s Jiangsu Tobacco Monopoly Bureau and Drug Regulator Target Illegal Vape Sales Disguised as Medical Devices, Define Six Violations
China’s Jiangsu Tobacco Monopoly Bureau and Jiangsu Provincial Medical Products Administration have issued a joint notice targeting illegal production and sales of vape products disguised as medical devices. The notice identifies six categories of violations, including obtaining medical licenses through false materials, misusing medical device credentials, expanding production beyond approved scopes, and using medical device-related online platforms to promote or sell vape products. The action is based on China’s tobacco and medical device regulations and aims to strengthen vape oversight and consumer protection.
Aug.04
2FIRSTS EXCLUSIVE|China Breaks Up $6.8 Million Illegal Hookah Tobacco Operation as Market Expands
2FIRSTS EXCLUSIVE|China Breaks Up $6.8 Million Illegal Hookah Tobacco Operation as Market Expands
Chinese authorities have dismantled an illegal hookah tobacco operation worth more than 46 million yuan ($6.8 million), detaining five foreign suspects and seizing over 500,000 boxes of tobacco paste. The case comes as hookah expands across China’s nightlife sector and attracts overseas operators, including former vaping entrepreneurs. It also raises a central regulatory question: whether waterpipe tobacco will follow China’s private-sector e-cigarette licensing model or be reserved for the state tobacco system, as with nicotine pouches, in the years ahead.
Jul.31